Development of conjugate-able temperature-responsive magnetic nanoparticles


To develop and validate technology for increasing the speed and efficiency of cell separations

Anticipated Impact: 

Efficient and cost-effective isolation of patients’ cells for cancer immunotherapy and other medical applications


Previous LSDF funding supported the optimization and scale-up of Nexgenia’s technology to improve the speed and sensitivity of immunoassays for clinical diagnosis. This technology consists of “smart” magnetic nanoparticles (mNPs) and polymers that can be conjugated to antibodies against various biomarkers. When a stimulus is applied, the mNPs and polymer-antibody-biomarker conjugates rapidly form aggregates that can be separated for analysis. The current grant focuses on adaptation and extension of this technology to enhance the speed and cost-efficiency of cell separations (isolation of cells expressing specific surface proteins from a mixed population). Improved cell separations approaches are particularly needed in the emerging area of cancer immunotherapy, a field that is attracting significant clinical interest and venture investment. This grant will support synthesis of reagents and assessment of their efficacy for cell separations. A successful outcome is anticipated to position Nexgenia for investment and strategic partnerships.

Nexgenia named Ron Myers as principal investigator, replacing Thomas Schulte, in October 2014.

Cell Separations Technology

Grant Update

Principal Investigator:
Ron Myers
Grantee Organization:
Nexgenia, Inc.
Grant Title:
Development of conjugate-able temperature-responsive magnetic nanoparticles
Grant Cohort and Year:
2014 Proof of Concept (03)
Grant Period:
11/01/2014 - 10/31/2016 (Completed)
Grant Amount:
With LSDF funding, Nexgenia continues its research and development around stimuli-responsive polymer reagents for life science and diagnostics applications. These polymers have been integrated into Nexgenia’s proprietary process for synthesizing stimuli-responsive magnetic nanoparticles. The magnetic nanoparticles are synthesized at scales that provide sufficient material for extensive internal characterization in addition to evaluation by external partners. Nexgenia is working to conjugate targeted antibodies to the magnetic nanoparticles for evaluation internally and by external partners in cell separations and diagnostics assays.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
11, 34, 36, 37, 43, 46

Health Impacts

Cell Separations Technology